The abovementioned results not only emphasize the centrality of metformin in the treatment of DKD but also point out the utilization of GLP-1R agonists as an emerging therapeutic strategy in the prevention and treatment of DKD. This evidence concerns the gene GLP1R and diabetic kidney disease.